| William C Johnson Iii, MD | |
|
1026 N Flowood Dr, Flowood, MS 39232-9532 | |
| (601) 932-1000 | |
| Not Available |
| Full Name | William C Johnson Iii |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 35 Years |
| Location | 1026 N Flowood Dr, Flowood, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649386392 | NPI | - | NPPES |
| 00116953 | Medicaid | MS | |
| 05004783 | Other | MS | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 14875 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Merit Health Women's Hospital | Flowood, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lakeland Anesthesia, Pllc | 0941102719 | 13 |
News Archive
More than one in six Americans younger than 65 could have access to help with their health insurance costs as a result of the health law. Red and blue congressional districts look remarkably similar here. Republican districts have, on average, an estimated 18 percent of the nonelderly people eligible for help with health insurance costs under the reform law. Democratic districts have about the same, 17 percent.
Pregnant women in poor communities in Bangladesh who received multiple micronutrients, including iron and folic acid combined with early food supplementation, had substantially improved survival of their newborns, compared to women in a standard program that included usual food supplementation, according to a study in the May 16 issue of JAMA, a theme issue on Global Health.
Circumcision performed between ages 3 to 6 years does not adversely affect men's psychosexual function during adulthood, report Turkish researchers.
A new approach to combatting tuberculosis would take advantage of a complex, natural process called autophagy that the human body uses to recycle nutrients, remove damaged cell components, eliminate invading bacteria, and respond to inflammation.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 6 days ago
| Entity Name | Lakeland Anesthesia, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053358937 PECOS PAC ID: 0941102719 Enrollment ID: O20040122000612 |
News Archive
More than one in six Americans younger than 65 could have access to help with their health insurance costs as a result of the health law. Red and blue congressional districts look remarkably similar here. Republican districts have, on average, an estimated 18 percent of the nonelderly people eligible for help with health insurance costs under the reform law. Democratic districts have about the same, 17 percent.
Pregnant women in poor communities in Bangladesh who received multiple micronutrients, including iron and folic acid combined with early food supplementation, had substantially improved survival of their newborns, compared to women in a standard program that included usual food supplementation, according to a study in the May 16 issue of JAMA, a theme issue on Global Health.
Circumcision performed between ages 3 to 6 years does not adversely affect men's psychosexual function during adulthood, report Turkish researchers.
A new approach to combatting tuberculosis would take advantage of a complex, natural process called autophagy that the human body uses to recycle nutrients, remove damaged cell components, eliminate invading bacteria, and respond to inflammation.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William C Johnson Iii, MD Po Box 321360, Flowood, MS 39232-1360 Ph: (601) 936-0681 | William C Johnson Iii, MD 1026 N Flowood Dr, Flowood, MS 39232-9532 Ph: (601) 932-1000 |
News Archive
More than one in six Americans younger than 65 could have access to help with their health insurance costs as a result of the health law. Red and blue congressional districts look remarkably similar here. Republican districts have, on average, an estimated 18 percent of the nonelderly people eligible for help with health insurance costs under the reform law. Democratic districts have about the same, 17 percent.
Pregnant women in poor communities in Bangladesh who received multiple micronutrients, including iron and folic acid combined with early food supplementation, had substantially improved survival of their newborns, compared to women in a standard program that included usual food supplementation, according to a study in the May 16 issue of JAMA, a theme issue on Global Health.
Circumcision performed between ages 3 to 6 years does not adversely affect men's psychosexual function during adulthood, report Turkish researchers.
A new approach to combatting tuberculosis would take advantage of a complex, natural process called autophagy that the human body uses to recycle nutrients, remove damaged cell components, eliminate invading bacteria, and respond to inflammation.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 6 days ago
Dr. Merrill D Hardy Jr., M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2550 Flowood Dr, Suite 400, Flowood, MS 39232 Phone: 601-933-9521 Fax: 601-933-9525 | |
Dr. Constantine P Zouboukos, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2550 Flowood Dr, Suite 400, Flowood, MS 39232 Phone: 601-933-9521 Fax: 601-933-9525 | |
Thomas D Buford, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 120 Stone Creek Blvd Ste 500, Flowood, MS 39232 Phone: 601-420-2040 Fax: 601-420-2356 | |
Sarah H Hines, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1026 N Flowood Dr, Flowood, MS 39232 Phone: 601-936-0681 Fax: 601-936-0686 | |
Dr. Lee E Herring, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2550 Flowood Dr, Suite 400, Flowood, MS 39232 Phone: 601-933-9521 Fax: 601-933-9525 | |
Billie W. Bruner, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1026 N Flowood Dr, Flowood, MS 39232 Phone: 601-936-0681 Fax: 601-936-0686 | |
Dr. Stephen R Snypes, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2550 Flowood Dr, Suite 400, Flowood, MS 39232 Phone: 601-933-9521 Fax: 601-933-9525 |